Results 11 to 20 of about 61,476 (246)

CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review

Current Issues in Molecular Biology, 2023
Genomic alterations of CDKN2A and CDKN2B in astrocytomas have been an evolving area of study for decades. Most recently, there has been considerable interest in the effect of CDKN2A and/or CDKN2B (CDKN2A/B) homozygous deletions (HD) on the prognosis of ...
Alexander Yuile, Laveniya Satgunaseelan, Joe Q. Wei, Michael Rodriguez, Michael Back, Nick Pavlakis, Amanda Hudson, Marina Kastelan, Helen R. Wheeler, Adrian Lee   +9 more
doaj   +2 more sources

Cdkn2a deficiency promotes adipose tissue browning

Molecular Metabolism, 2018
Objectives: Genome-wide association studies have reported that DNA polymorphisms at the CDKN2A locus modulate fasting glucose in human and contribute to type 2 diabetes (T2D) risk.
Nabil Rabhi, Sarah Anissa Hannou, Xavier Gromada, Elisabet Salas, Xi Yao, Frédérik Oger, Charlène Carney, Isabel C. Lopez-Mejia, Emmanuelle Durand, Iandry Rabearivelo, Amélie Bonnefond, Emilie Caron, Lluis Fajas, Christian Dani, Philippe Froguel, Jean-Sébastien Annicotte   +15 more
doaj   +2 more sources

Revisiting CDKN2A dysregulation in Ewing sarcoma

Molecular Oncology
Ewing sarcoma (EwS) is a rare and aggressive malignancy, which frequently affects children. One of the few recurrent genomic variants in EwS is genomic copy number deletion of CDKN2A; however, the clinical consequences of dysregulation of CDKN2A in EwS ...
Anjali Paragji, Vivek Shastri, Elham Nasri, John A. Ligon, Leighton A. Elliott, Paul Castillo‐Caro, Jatinder K. Lamba, Elias J. Sayour, Nathan D. Seligson   +8 more
doaj   +2 more sources

Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas [PDF]

Journal of Experimental & Clinical Cancer Research, 2011
Background Malignant gliomas are the most common in central nervous system cancer. Genome-wide association study identifies that CDKN2A was a susceptibility loci for glioma.
li Lei, Li Yawei, Lv Guohua, Liu Weidong, Wang Bing   +4 more
doaj   +2 more sources

Frequency and Prognostic Impact of CDKN2A/B Alteration in Oligodendrogliomas: Systematic Review and Meta-analysis

Neurologia Medico-Chirurgica
Isocitrate dehydrogenase (IDH)-mutant astrocytomas with homozygous deletion of cyclin-dependent kinase 2A/B (CDKN2A/B-HomoD) are categorized to grade 4 in the new World Health Organization (WHO) classification.
Satoshi NAKASU, Shoichi DEGUCHI, Yoko NAKASU   +2 more
doaj   +2 more sources

FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma [PDF]

, 2023
Deletion of CDKN2A occurs in 50% of glioblastomas (GBM), and IFNA locus deletion in 25%. These genes reside closely on chromosome 9. We investigated whether CDKN2A and IFNA were co-deleted within the same heterogeneous tumour and their prognostic ...
Mryyian, Amel, Dawoud, Rand, Brennan, Paul M, Singh, Ashita, Saleh, Tareq, Abu Al Karsaneh, Ola, Ball, Kathryn, Hupp, Ted, Al Shboul, Sofian, Alrjoub, Moath, Gul, Sinem, Boyle, Shelagh, Abu Baker, Shaden   +12 more
core   +1 more source

Association of MC1R Variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study [PDF]

, 2010
<p><b>Background</b> Carrying the cyclin-dependent kinase inhibitor 2A (CDKN2A) germline mutations is associated with a high risk for melanoma. Penetrance of CDKN2A mutations is modified by pigmentation characteristics, nevus phenotypes,
Pastorino, L., Melanoma Genetics Consortium, Goldstein, A M, Taylor JC, Ming M, Taylor Y, Martin NG, PUIG S, Rull R, Gliori S, Holland EA., Gonzalez M, Calista, D, Mackie, R.M., Lindén D, N. K. Hayward, Randerson-Moor, J, Palou J, Vilalta A, Ming, M. E., V. Höiom, Belle, P. van, Conill C, Gillanders, E, Avril, M.F., Vidal-Sicart S, Carrera, C., Bishop, J.A.N., Lang, J. M., Bishop, D. T., Mohamdi, H., GRUIS N, Bressac-de Paillerets, B, BIANCHI-SCARRÀ G, Gruis NA, P. A. Kanetsky, Bressac-de Paillerets, B., Malvehy J, N. Gruis, Whiteman DC, CARRERA C, Hayward, N. K., Tucker, M.A., G. J. Mann, van der Velden, P, Badenas C, R. M. Mackie, Stark, M., Nasti S, Marti-Laborda R, GenoMEL, Harbst K, V. Chaudru, RANDERSON-MOOR J, B. Bressac-de Paillerets, C. Ingvar, ELDER DE, PASTORINO L, J. Randerson-Moor, Tsao, H, Mohamdi, H, Landi G, Cuellar F, HAYWARD NK, AVRIL MF, Brassac-de Paillerets, B., Minghetti P, van Belle, P., Carrera, C, C. J. Njauw, Kanetsky P, E. Gillanders, A. M. Goldstein, Calista, D., Hayward, N K, Gargiulo S, W. BRUNO, Kanetsky, P.A., Arguís P, Bianchi-Scarra, G., L. Pastorino, D. E. Elder, Bertazzi PA, BERGMAN W, Chaudru, V, Mackie, R M, HÖIOM V, Battistuzzi L, Duffy DL, Origone P, Elder, D. E., Holland, E.A., HANSSON J, MacGregor S, MANN GJ, TUCKER MA, Mack T, Lang, J.M., F. Demenais, X. R. Yang, Ancero A, de Lichy M, Newton Bishop, J. A., Bianhi-Scarrà G, Landi, MT, Leake S, Mann, G J, Landi, M.T., VAN BELLE P, Stark, M, Hayward, N.K., van Mourik L, Yang, X.R., Parossian S, Demenais, F, Nielsen K, Elder, D.E., Tsao, H., Arcangeli F, Montgomery GW, MOHAMDI H, CHAUDRU V, J. Palmer, Mackie, R., M. E. Ming, Demenais, F., AZIZI E, Ming, M E, M. T. Landi, Azizi, E., Holland, E A, Randerson-Moor, J., Alós L, Gruis, N, Olsson, Håkan, J. M. Lang, van Nieuwpport FA, Castel T, LANDI MT, LANG JM, M. F. Avril, Haynes S, Kanetsky, P. A., Queirolo P, Karpavicius B, BISHOP DT, Palmer, J., M. Harland, Hogg, D., J. Hansson, CALISTA D, VAN DER VELDEN P, van der Velden, P., Yang, X R, Chaudru, V., Bergman, W., van Belle, P, Chan M, Höiom, V, BRUNO W, Kanetsky, P A, PALMER J, NJAUW CJ, Lang, J., H. Tsao, Sánchez M, G. Bianchi-Scarrà, Vilella R, NEWTON BISHOP JA, Avril, M F, Maubec E, Goldstein, A.M., P. van der Velden, J. A. Newton Bishop, KANETSKY PA, Mila M, Hoiom, V., Melanoma Genetics Consortium: Demenais F, H. Olsson, BRESSAC-DE PAILLERETS B, Harland, M, Tuominen R, E. A. Holland, Affleck P, Whittaker L, Loo JC, Mackie, R. M., Tesema L, Njauw, C. J., Iles MM, Borg Å, Holland, E. A., Ingvar, Christian, MACKIE RM, Hansson, J., HOLLAND EA, GHIORZO P, Butille JA, Cervera R, Ogbah Z, Azizi, E, Bishop, D.T., C. Carrera, Velden, P. van der, Landi, M. T., Campo A, Ming, M.E., Newton Bishop, J A, Jeannin P, Lang, J M, Bishop, D T, MING ME, Njauw, C J, E. Azizi, HARLAND M, Lang J, M. A. Tucker, Elder D, Gabriel D, Gruis, N., Gillanders, E., W. Bergman, Lesueur F, Capirossi D, DEMENAIS F, STARK M, Mackie R, Ingvar, C., GILLANDERS E, Njauw, C.J., P. van Belle, Barrett JH, GOLDSTEIN AM, M. Stark, Hogg, D, Iglesias P, Puig, S., D. Hogg, Elder, D E, INGVAR C, Kukalizch K, Mann, G.J., Olsson, H., Bergman, W, Pastorino, L, Mann, G. J., S. Puig, Schmid H, Tucker, M A, D. Calista, Mitra N, TSAO H, YANG XR, Kefford RF, P. GHIORZO, Njauw CN, Avril, M. F., Jönsson G, Harrison J, HOGG D, Ruffin A, Aguilera P, D. T. Bishop, Corda E, OLSSON H, Puig, S, Hansson, J, Palmer, J, Bianchi-Scarrà, G, H. Mohamdi, Måsbäck A, Newton Bishop, J.A., Harland, M., Goldstein, A. M., Olsson, Håkan,, Bishop, DT, Ingvar, Christian,, Hayward, NK, Bishop, JAN, Lund University., Goldstein, AM, Kanetsky, PA, Elder, DE   +282 more
core   +1 more source

Stimulation of epidermal hyperplasia and tumorigenesis by resident p16INK4a-expressing cells

Molecular & Cellular Oncology, 2020
p16INK4a (CDKN2A) is a central tumor-suppressor and activator of senescence. We recently found that prolonged expression of p16INK4a in epidermal cells induces hyperplasia and dysplasia through Wnt-mediated stimulation of neighboring keratinocytes.
Narmen Azazmeh, Ittai Ben-Porath
doaj   +1 more source

P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas

Acta Neuropathologica Communications, 2023
Molecular characterization of gliomas has uncovered genomic signatures with significant impact on tumor diagnosis and prognostication. CDKN2A is a tumor suppressor gene involved in cell cycle control.
Meenakshi Vij, Benjamin B. Cho, Raquel T. Yokoda, Omid Rashidipour, Melissa Umphlett, Timothy E. Richardson, Nadejda M. Tsankova   +6 more
doaj   +1 more source

Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of SPATS2L in Patients With Glioma

Frontiers in Oncology, 2021
Purpose: This study was conducted in order to analyze the prognostic effects of epidermal growth factor receptor (EGFR) and CDKN2A alterations and determine the prognostic significance of EGFR and CDKN2A alterations on regulated genes in patients with ...
Haiwei Wang, Xinrui Wang, Liangpu Xu, Ji Zhang, Hua Cao   +4 more
doaj   +1 more source